Studies of the novel chemotherapeutic drugs for herpesvirus infections

原发性渗出性淋巴瘤(PEL)是一种非霍奇金B细胞淋巴瘤，与免疫功能低下的患者有关，如艾滋病患者。PEL细胞普遍感染卡波西肉瘤相关疱疹病毒(KSHV)。在此之前，我们已经开发了抗肿瘤化合物CNDAG及其衍生物，可以诱导PEL细胞凋亡。为了建立有效的治疗PEL和KSHV感染的方法，我们论证了CNDAG的作用机制和新的功能，即抗疱疹病毒活性。我们进一步鉴定了参附霉素、富勒烯类似物和丙戊酸钠为新的抗PEL化合物。

Primary effusion lymphoma (PEL) is classified as non-Hodgkin's B-cell lymphoma associated with immunocompromised patients such as AIDS patients. PEL cells are universally infected with Kaposi's sarcoma-associated herpesvirus (KSHV). Previously, we had developed anti-tumor compounds, CNDAG and its derivatives, which induce apoptosis in PEL cells. To establish the effective treatment for PEL and KSHV infection, we have demonstrated the mechanisms of action of CNDAG and novel functions, namely anti-herpesviral activities. We furthermore identified sangivamycin, fullerene analogues and sodium valproate as new anti-PEL compounds.